Adenoviral Vector (AdV) Packaging

1. Technical Background and Principles

Recombinant adenovirus (rAdV) is a replication-deficient viral vector system produced by genetic engineering, playing an important role in gene therapy, vaccine development, basic life science research, and clinical applications. The adenoviral vector platform we employ is based primarily on Human Adenovirus serotype 5 (Ad5), whose genome consists of a 36 kb linear double-stranded DNA molecule.

Fig1. Adenovirus (AdV) structure (Coughlan, Lynda. 2020)

2. Infection Mechanism

Adenovirus enters host cells by binding its surface fiber protein to the Coxsackievirus and Adenovirus Receptor (CAR) on the cell surface, followed by receptor-mediated endocytosis. After escaping from the endosome, viral particles translocate to the cytoplasm and ultimately enter the nucleus, where they utilize the host cell's transcription and translation machinery to achieve high-level expression of the gene of interest.

3. Vector System Advantages

Our recombinant adenoviral vector system has been carefully engineered with deletions in the E1 and E3 gene regions, ensuring the virus is incapable of completing a replication cycle in target cells and thereby guaranteeing biosafety. Simultaneously, this design provides ample packaging capacity for insertion of exogenous genetic material (accommodating up to approximately 8 kb of foreign DNA).

4. Professional Service Solutions

Drawing on years of accumulated viral vector platform expertise and extensive project experience, Zhuhai GeneRulor provides comprehensive customized adenoviral vector services to research institutes, biotechnology companies, and pharmaceutical enterprises. Services include:

4.1 Gene Function Research Vectors

• Conventional gene overexpression vector construction

• RNAi-mediated gene silencing vectors

• Tissue-specific promoter-driven vector systems

4.2 Non-Coding RNA Research Vectors

• circRNA overexpression and loss-of-function vectors

• LncRNA expression and regulation vectors

• Custom miRNA/siRNA vectors

4.3 Gene Editing Tool Vectors

• CRISPR/Cas9 system vectors

• Prime editing vectors

• Base editing vector systems

4.4 Vaccine and Therapeutic Vectors

• Tumor immunotherapy vectors

• Vaccine antigen display vectors

• Oncolytic virus vector development

4.5 Service Specifications and Pricing

5. Technical Advantages and Features

5.1 Broad Host Cell Infectivity

Adenoviral vectors possess a wide host cell range, capable of efficiently infecting diverse mammalian cell types, including:

• Proliferating cells (e.g., tumor cell lines, primary cultured cells)

• Terminally differentiated cells (e.g., neurons, cardiomyocytes, hepatocytes)

• Stem cells and progenitor cells

5.2 Outstanding Transduction Efficiency

Under optimized experimental conditions, our adenoviral vectors achieve:

• Cell infection rate: up to 95–100%

• Gene expression level: 10–100-fold higher than plasmid transfection

• Expression duration: stable high-level expression for 7–14 days

5.3 High-Titer Preparation Technology

Employing advanced manufacturing processes and purification technology:

• Viral titer: concentrable to 10¹²–10¹³ vp/mL

• Infectious titer: reaching 10¹⁰–10¹¹ PFU/mL

• vp/PFU ratio: optimized and controlled within 10–100

5.4 Convenient Amplification Characteristics

Compared with other viral vector systems:

• No re-packaging required; can be directly amplified

• Short production cycle with high cost-effectiveness

• Suitable for large-scale preparation

5.5 Superior Biosafety Profile

Key safety features of the adenoviral vector system include:

• Non-integrating: does not insert into the host cell genome, eliminating the risk of insertional mutagenesis

• Replication-deficient: E1/E3 deletions prevent autonomous replication

• Controllable immunogenicity: immune responses can be reduced through serotype selection

5.6 Stable Physicochemical Properties

Adenoviral vectors exhibit excellent storage stability:

• Storage at 4°C: activity maintained for several weeks

• Storage at −80°C: stable for several years

• Freeze-thaw stability: tolerates multiple freeze-thaw cycles

6. Quality Control System

We have established a comprehensive quality management system to ensure every batch of product meets standards:

6.1 Pathogen Testing

6.2 Biological Activity Testing

7. Application Areas

7.1 basic scientific research

• Gene function validation and phenotypic analysis

• Signal pathway research

• Disease mechanism exploration

• Drug screening platforms

7.2 Translational Medicine Research

• Gene therapy vector development

• Tumor immunotherapy

• Vaccine vector platforms

• Cell reprogramming research

7.3 Preclinical Research

• Animal model construction

• Pharmacodynamic evaluation

• Safety assessment

• Dose optimization studies

8. Technical Support and After-Sales Service

References

[1] Coughlan, Lynda. Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines. Frontiers in Immunology vol. 11, 909. 19 May 2020. doi:10.3389/fimmu.2020.00909.

[2] Xu, Jinghan et al. Development of a novel adenovirus type 4 vector as a promising respiratory vaccine vehicle. Frontiers in Immunology vol. 16, 1572081. 10 Apr. 2025. doi:10.3389/fimmu.2025.1572081.

[3] Yu, TaChung et al. Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. Cell vol. 170,3 (2017): 548–563.e16. doi:10.1016/j.cell.2017.07.008.

[4] Xu, Lingyan et al. Heat shock factor 1 in fat biology: comments on 'Local hyperthermia therapy induces browning of white fat and treats obesity'. Journal of Molecular Cell Biology.